{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:55Z","timestamp":1794047455780,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Immunoparesis (IP) in multiple myeloma (MM) patients can be measured by classic assessment of immunoglobulin (Ig) levels or by analysis of the uninvolved heavy\/light chain pair of the same immunoglobulin (uHLC) by the Hevylite\u00ae\uf87f assay. In this study we evaluate the prognostic value of recovery from IP measured by classic total Ig and uHLC assessment in newly diagnosed MM transplant-eligible (NDMM-TE) patients with intensive treatment and its association with minimal residual disease (MRD). Patients were enrolled and treated in the PETHEMA\/GEM2012MENOS65 trial and continued in the PETHEMA \/GEM2014MAIN trial. Total Ig (IgG, IgA and IgM) and uHLC were analyzed in a central laboratory at diagnosis, after consolidation treatment and after the first year of maintenance. MRD was analyzed by next-generation flow cytometry after consolidation (sensitivity level 2x10-6). We found no differences in progression-free survival (PFS) between patients who recovered and patients who didn\u2019t recover from IP after consolidation when examining classic total Ig and uHLC. However, after the first year of maintenance, in contrast to patients with classic IP, patients with recovery from uHLC IP had longer PFS than patients without recovery, with hazard ratio of 0.42 (95% confidence interval [CI]: 0.21-0.81; P=0.008). Multivariate analysis with Cox proportional-hazards regression models confirmed recovery from uHLC IP after the first year of maintenance as an independent prognostic factor for PFS, with an increase in C-statistic of 0.05 (95% CI: -0.04 to 0.14; P&lt;0.001) when adding uHLC IP recovery. Moreover, we observed that MRD status and uHLC IP recovery affords complementary information for risk stratification. In conclusion, recovery from uHLC IP after 1 year of maintenance is an independent prognostic factor for PFS in NDMM-TE patients who receive intensive treatment. Immune reconstitution, measured as recovery from uHLC IP, provides complementary prognostic information to MRD assessment (clinicaltrials gov. Identifiers: NCT01916252 and NCT02406144).<\/jats:p>","DOI":"10.3324\/haematol.2023.284154","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:05Z","timestamp":1701315605000},"page":"1909-1917","source":"Crossref","is-referenced-by-count":4,"title":["Recovery of uninvolved heavy\/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection"],"prefix":"10.3324","volume":"109","author":[{"given":"Sunil","family":"Lakhwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Pico-Picos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Medina-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jes\u00fas","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Jarque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"Moraleda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estrella","family":"Carrillo-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Krsnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"De Arriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Gonz\u00e1lez-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Motll\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Teodoro","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"62283","doi-asserted-by":"crossref","unstructured":"Kastritis E, Zagouri F, Symeonidis A. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia. 2014; 28(10):2075-2079.","DOI":"10.1038\/leu.2014.110"},{"key":"62284","doi-asserted-by":"crossref","unstructured":"Heaney JLJ, Campbell JP, Iqbal G. Characterization of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018; 32(8):1727-1738.","DOI":"10.1038\/s41375-018-0163-4"},{"key":"62285","doi-asserted-by":"crossref","unstructured":"S\u00f8rrig R, Klausen TW, Salomo M. Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population. PLoS One. 2017; 12(12):e0188988.","DOI":"10.1371\/journal.pone.0188988"},{"key":"62286","doi-asserted-by":"crossref","unstructured":"Ludwig H, Milosavljevic D, Berlanga O. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed\/refractory patients with myeloma. Am J Hematol. 2016; 91(3):295-301.","DOI":"10.1002\/ajh.24268"},{"key":"62287","doi-asserted-by":"crossref","unstructured":"Boyle EM, Fouquet G, Guidez S. IgA kappa\/IgA lambda heavy\/light chain assessment in the management of patients with IgA myeloma [published correction appears in Cancer. 2015 Mar 1;121(5):800]. Cancer. 2014; 120(24):3952-3957.","DOI":"10.1002\/cncr.28946"},{"key":"62288","doi-asserted-by":"crossref","unstructured":"Geng C, Yang G, Wang H. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2021; 62(4):883-890.","DOI":"10.1080\/10428194.2020.1855345"},{"key":"62289","doi-asserted-by":"crossref","unstructured":"Koulieris E, Panayiotidis P, Harding SJ. Ratio of involved\/ uninvolved immunoglobulin quantification by Hevylite\u2122 assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol. 2012; 1(1):9.","DOI":"10.1186\/2162-3619-1-9"},{"key":"62290","unstructured":"D\u00edaz-Rodr\u00edguez R, F\u00e9rnandez-Gonz\u00e1lez M, Mart\u00edn-Mart\u00edn A. Resoluci\u00f3n de la inmunoparesia como par\u00e1metro de la remisi\u00f3n completa real en el mieloma m\u00faltiple. LV National Congress of SEHH and XXIX National Congress of SETH, Sevilla. 2013:CO-021. 2023. Publisher Full Text|"},{"key":"62291","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Calle V, Cerd\u00e1 S, Labrador J. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017; 102(5):922-931.","DOI":"10.3324\/haematol.2016.158345"},{"key":"62292","doi-asserted-by":"crossref","unstructured":"Jimenez-Zepeda VH, Duggan P, Neri P, Chaudhry A, Tay J, Bahlis N. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leuk Lymphoma. 2018; 59(8):1920-1926.","DOI":"10.1080\/10428194.2017.1403026"},{"key":"62293","doi-asserted-by":"crossref","unstructured":"D\u00e1vila J, Gonz\u00e1lez-Calle V, Escalante F. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival. Br J Haematol. 2022; 198(2):278-287.","DOI":"10.1111\/bjh.18182"},{"key":"62294","doi-asserted-by":"crossref","unstructured":"Ozaki S, Harada T, Yagi H. Polyclonal immunoglobulin recovery after autologous stem cell transplantation is an independent prognostic factor for survival outcome in patients with multiple myeloma. Cancers (Basel). 2019; 12(1):12.","DOI":"10.3390\/cancers12010012"},{"key":"62295","doi-asserted-by":"crossref","unstructured":"Eisfeld C, E\u00dfeling E, Wullenkord R. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma. Ann Hematol. 2020; 99(8):1907-1915.","DOI":"10.1007\/s00277-020-04068-5"},{"key":"62296","doi-asserted-by":"crossref","unstructured":"Harutyunyan NM, Vardanyan S, Ghermezi M. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients. Br J Haematol. 2016; 174(1):81-87.","DOI":"10.1111\/bjh.14026"},{"key":"62297","doi-asserted-by":"crossref","unstructured":"Suehara Y, Takamatsu H, Fukumoto K. Abnormal heavy\/ light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. Cancer Sci. 2017; 108(2):187-192.","DOI":"10.1111\/cas.13125"},{"key":"62298","doi-asserted-by":"crossref","unstructured":"R\u00edos-Tamayo R, Puig N, Algar\u00edn M. The current role of the heavy\/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: an evidence-based approach. Diagnostics (Basel). 2021; 11(11):2020.","DOI":"10.3390\/diagnostics11112020"},{"key":"62299","doi-asserted-by":"crossref","unstructured":"Paiva B, Puig N, Cedena MT. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020; 38(8):784-792.","DOI":"10.1200\/JCO.19.01231"},{"key":"62300","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Ludwig H, Landgren O. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020; 20(1):e30-e37.","DOI":"10.1016\/j.clml.2019.09.622"},{"key":"62301","doi-asserted-by":"crossref","unstructured":"Mohan M, Kendrick S, Szabo A. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022; 6(3):808-817.","DOI":"10.1182\/bloodadvances.2021005822"},{"key":"62302","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"62303","doi-asserted-by":"crossref","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos-Tamayo R. Ixazomib plus lenalidomide\/ dexamethasone (IRd) versus lenalidomide\/dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: results of the Spanish GEM2014MAIN Trial. Blood. 2021; 138(Suppl 1):466.","DOI":"10.1182\/blood-2021-146798"},{"key":"62304","doi-asserted-by":"crossref","unstructured":"Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020; 136(24):2731-2740.","DOI":"10.1182\/blood.2020006540"},{"key":"62305","doi-asserted-by":"crossref","unstructured":"Tovar N, de Larrea CF, Ar\u00f3stegui JI. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution. Haematologica. 2013; 98(7):1142-1146.","DOI":"10.3324\/haematol.2013.084350"},{"key":"62306","doi-asserted-by":"crossref","unstructured":"Paiva B, Cedena MT, Puig N. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016; 127(25):3165-3174.","DOI":"10.1182\/blood-2016-03-705319"},{"key":"62307","doi-asserted-by":"crossref","unstructured":"Mazahreh F, Mazahreh L, Schinke C. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023; 7(13):3069-3074.","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"62308","doi-asserted-by":"crossref","unstructured":"Wang Y, Li C, Xia J. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Adv. 2021; 5(23):5290-5299.","DOI":"10.1182\/bloodadvances.2021004603"},{"key":"62309","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022; 139(4):492-501.","DOI":"10.1182\/blood.2020010439"},{"key":"62310","doi-asserted-by":"crossref","unstructured":"Bertuglia G, Cani L, Larocca A, Gay F, D\u2019Agostino M. Normalization of the immunological microenvironment and sustained minimal residual disease negativity: do we need both for long-term control of multiple myeloma?. Int J Mol Sci. 2022; 23(24):15879.","DOI":"10.3390\/ijms232415879"},{"key":"62311","doi-asserted-by":"crossref","unstructured":"Costa LJ, Chhabra S, Medvedova E. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol. 2022; 40(25):2901-2912.","DOI":"10.1200\/JCO.21.01935"},{"key":"62312","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Oliva S, Rota-Scalabrini D. Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial. Clin Lymphoma Myeloma Leuk. 2022; 22(Suppl):S6-7.","DOI":"10.1016\/S2152-2650(22)00284-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284154\/76375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284154\/77070","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11366\/76375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:18Z","timestamp":1794045918000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284154","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}